COO · Cardiff Oncology, Inc. (CRDF)

Vicki Kelemen

A named executive officer of Cardiff Oncology in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,829,877

Salary $359,962Stock awards $0

FY2020: $749,619

3rd of 3 named executive officers at Cardiff Oncology by FY2021 total.

3 named officers on file for Cardiff Oncology, FY2021

Vicki Kelemen’s pay file — $29

  • 2 fiscal years of pay, line by line
  • CRDF’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Cardiff Oncology’s whole pay program stands against its peers

  • Cardiff Oncology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CRDF→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 14, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Vicki Kelemen’s full pay file as a PDF — free

More than this page: up to 10 years of Vicki’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Vicki Kelemen compensation by year

Cardiff Oncology Summary Compensation Table · all 2 fiscal years held
In US dollars, as Cardiff Oncology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$322,576$359,962
Bonus$0$0
Stock awards$0$0
Option awards$269,543$1,317,635
Non-equity incentive$157,500$152,280
Pension and deferred compensation$0$0
All other$0$0
Total$749,619$1,829,877

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cardiff Oncology, Inc. DEF 14A filed April 14, 2022, accession 0001628280-22-009196, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Cardiff Oncology, Inc. filed document, accession 0001628280-22-009196. Every figure is read from that document and cited to the page and table it appears in. Filed April 14, 2022.

$750K
$1.8M
FY20
FY21
SalaryNon-equity incentiveOption awards

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option35,320—$2.48
Option83,366—$2.60
Option200,928—$7.98

Per the Outstanding Equity Awards at Fiscal Year-End table in Cardiff Oncology, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1 Form 4 line since the FY2021 proxy (filed April 14, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2023-03-15Grant or award derivative—125,520$0.00698,304

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Cardiff Oncology’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Mark ErlanderCEO$3,635,198
James LevineCFO$2,467,695
Vicki Kelemen · this pageCOO$1,829,877

The full Cardiff Oncology compensation record

free company brief

This page is one person within Cardiff Oncology's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cardiff Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Vicki Kelemen's compensation dossier · One-time report. No refunds.